Lysosomal storage disease (LTD) is caused by defect in lysosomal functions and degradation pathway. It is caused by progressive accumulation of metabolites. LTD is a rare inherited metabolic disorder. There are 50 types of lysosomal storage diseases. Lysosomes are organelle present in eukaryotic cell. These consist of degradative enzymes enclosed in a membrane. A study conducted by Mayo Clinic in the U.S. indicated that the incidence of lysosomal disorder ranges between 1 in 4000 and 1 in 13,000 live births. Tay-Sachs disease was the first lysosomal disorder to be diagnosed in 1881.
Increase in incidence of lysosomal diseases, rise in diagnostic rate, surge in awareness about this rare disorder, increase in focus on research and development for diagnosis & drug development for treatment of lysosomal diseases, and implementation of orphan drug regulation that provides marketing and commercial benefits to pharmaceutical companies fuel the growth of the global lysosomal storage disease treatment market. However, high cost of available treatment, underdiagnosed lysosomal disorders because of heterogeneity of the rare lysosomal disorder, and decrease in efficiency of treatment option are likely to hamper the growth of the global lysosomal storage disease treatment market. Availability and advancement of chaperone and gene therapy is expected to propel the market during the forecast period.
The global lysosomal storage disease treatment market can be segmented based on disease type, therapy, end-user, and region. In terms of disease type, the global market can be classified into aspartylglucosaminuria, Batten disease, cystinosis, Fabry disease, Gaucher disease, glycogen storage disease II, Tay-Sachs disease, and others. Gaucher disease is the most common type of lysosomal disorder which is characterized by neurological complication. Tay-Sachs disease is another common lysosomal disorder propelling the global lysosomal storage disease treatment market.
Based on therapy, the global lysosomal storage disease treatment market can be categorized into enzyme replacement therapy, stem cell transplantation, substrate reduction therapy, and others. Enzyme replacement is the most preferred therapy for the treatment of lysosomal disorder. It is effective in reducing toxic storage material and organomegaly. Enzyme replacement therapy also helps in improving organ function in patients suffering from lysosomal disorder. Advanced research in stem cell transplantation has increased the success rate of treatment of lysosomal disease. Rise in the number of stem cell banks also fuels the growth of the global lysosomal storage disease treatment market.
In terms of end-user, the global lysosomal storage disease treatment market can be divided into hospitals, clinics, stem transplant centers, research organizations, and others. Hospitals was the leading segment of the global lysosomal storage disease treatment market in 2017. Research organizations are being funded by governments as well as pharmaceutical companies for the development of new treatment methods and drugs. Hence, the research organizations segment is expected to witness significant growth during the forecast period.
In terms of region, the global lysosomal storage disease treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is a leading market for lysosomal disease treatment because of strong health care, economic, and financial infrastructure. Europe is a major hub for health care research and development. Moreover, high per capita income of the people is attributed to the growth of the global lysosomal storage disease disorder treatment market in the region. Asia Pacific consists of developing countries with high prevalence of inherited abnormalities and disorders. Hence, the market in the region is expected to grow at a rapid pace during the forecast period.
Key players operating in the global lysosomal storage disease treatment market include Shire, Pfizer, Inc., Sanofi, BioMarin, Merck & Co., Inc., Actelion Pharmaceuticals Ltd., and Eli Lilly and Company.
This upcoming business intelligence report is intended to be a one-stop market research solution to guide organizations in taking timely and effective decisions for their business growth. The ongoing study is the culmination of our deep expertise on data science methods, combined with an unparalleled understanding of the external environment and analysis of the industries. Each of the reports by TMR aims at offering a detailed scrutiny of the value chain of our current and prospective customers, takes them from identifying value propositions, and subsequently assist their business executives to implement right strategies to create customer value. We believe that creating and sustaining the customer value is the key pivot on which business executives can create profits for their organizations and increase the market shares, continuously and with sustainability.
Each of our touchpoints through which we engage with the organization/enterprise during the primary research enables us to understand the internal environment it operates in and the ways in which the external environment influences its growth.
Always Evolving with Competition
Excellence is built into the DNA of TMR, and all our teams work collaboratively and committedly toward achieving that in whatever they do. From the very first interaction our teams of research analysts have with any interested market participant to the final preparation processes in each of our reports reflects a rigorous understanding of the dynamic industry environment that businesses operate in.
We relentlessly work to be a differentiator in whatever we do in the current era of hypercompetitive global environment. The result of our unceasing focus on excellence is reflected clearly in the insights and guidance we offer to our customers in order to empower them to create brand equity. Our simple yet very powerful underpinning for navigating the competition is to always keep evolving with changing business environments. Our close-kinit team of research analysts not only believe in this simple philosophy but also implement the same.
Constantly Innovating Our Research Methodologies and Models
We do not limit with any specific market research tool or one standard approach for obtaining or analyzing data. Undoubtedly, our report making process is ever-evolving to meet the customer needs and demands supported broadly by a vast knowledge of data science methods that we combine with business acumen our teams have built upon for several years. Evidently, our primary and secondary research data about customers and consumers have shown that we can go to any lengths to obtain them. This is followed by applying next-gen automation tools integrated with human judgement to clear the clutter, ascertain the most relevant and recent qualitative and quantitative insights, and package them in digestible chunks in our reports for our customers.
We Take Pride in No-One-Size-Fits-All Approach
Over the past several years, we have been conducting market intelligence studies across all industries for all types of organizations — big and small, profit and not-for-profit, and Fortune 500 and Unicorns, as we believe that a sound decision making must be based on no-one-size-fits-all approach. Without doubt, each of the organizations regardless of the industry they are in are affected differently by changes in political, economic, socio-culture, legal, ecological, and legal environments. The research models and the value chain analysis process that our analysts employ for conducting the study uphold this approach.
We look at myriad components of internal and external business environment affecting the growth strategies of organizations. Some of the broader aspects that we focus on are:
- Our team of Analysts and Support Teams always strive to see the bigger picture in life cycle stages of any industry
- The Teams focus on obtaining valuable insights into different models of competitive advantage while making an internal environment analysis
- They keep on modifying the value chain analysis processes of organizations to understand on how customer value is created
Some areas of assessing market dynamics that are used in the research models and methodologies adopted by our analysts can be summarized as:
- Corporate and business strategies underlying new brand positioning strategies
- Mapping for strategic planning for business units
- Various metrics for business portfolio analysis, including BCG matrix
- Value chain analysis
These will help create and sustain competitive advantage for our prospects and current customers.
Key focus areas and agenda that underpin and catalyze our primary and secondary research initiatives and endeavors are:
- What are some of the core competencies and distinctive competencies of new entrants and established players in the industry we are analyzing?
- What are some of the branding opportunities that are emerging at a rapid pace?
- What are the major competitive forces and elements of external environment shaping the industry life cycle stages of most organizations?
- Why some competitive strategies are popular than others among leaders in a certain market?
- What customer-based brand equity strategies companies have leveraged in a certain industry or set of related industries in a sector?
- What are some of the key pricing strategies that companies in an industry are implementing for marketing their products internationally?
- Identifying whether market-push or market-pull strategies are more relevant to a certain product or a service?
Disclaimer: This ongoing market research study is a meticulously planned activity where a broad array of factors and aspects that shape the marketing environment and industry are taken into account. However, keeping in mind the constantly changing nature of business dynamics and changing strategic intents, we are always actively making iterations and modifications in our approaches. As always, we are ready to tailor our insights and guidance to suit your requirements. Engage with us to know what more is there for your CXOs.